Literature DB >> 31034802

Clinical aspects of Alzheimer's disease.

Martina Zvěřová1.   

Abstract

Alzheimer's disease is a progressive, irreversible, incurable, neurodegenerative illness and the most common of the dementing disorders. It starts usually after 60 years of age and may span 8 to 12 years. The continuous and slow decline caused by this disease, is characterized by cognitive deterioration, loss of functional independence, changes in behaviour, and expanding needs for care. In the last three decades, the proteins predominating neuritic plaques and neurofibrillary tangles have been detected and researched: amyloid-beta protein in the plaques and hyperphosphorylated tau in the tangles. Alzheimer's disease is now considered a long-term process with a slow progress and with a prolonged development of pathological changes that precedes symptoms by years. AD is becoming one of the most problematic and expensive illness for the civilization, also known as "silent threat".
Copyright © 2019 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Beta amyloid; Clinical aspects; Dementia; Plaques; Tangles; Tau protein

Mesh:

Year:  2019        PMID: 31034802     DOI: 10.1016/j.clinbiochem.2019.04.015

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  14 in total

1.  Recent Advances in Understanding of Alzheimer's Disease Progression through Mass Spectrometry-Based Metabolomics.

Authors:  Jericha Mill; Lingjun Li
Journal:  Phenomics       Date:  2022-02-22

Review 2.  Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer's disease.

Authors:  Fabiha Zaheen Khan; Md Shaki Mostaid; Mohd Nazmul Hasan Apu
Journal:  Heliyon       Date:  2022-07-05

Review 3.  Role of Impaired Mitochondrial Dynamics Processes in the Pathogenesis of Alzheimer's Disease.

Authors:  Alexander V Blagov; Andrey V Grechko; Nikita G Nikiforov; Evgeny E Borisov; Nikolay K Sadykhov; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

Review 4.  Collapsin Response Mediator Proteins: Novel Targets for Alzheimer's Disease.

Authors:  Tam T Quach; Aubin Moutal; Rajesh Khanna; Nicholas P Deems; Anne-Marie Duchemin; Ruth M Barrientos
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

5.  Chronic Oral Palmitoylethanolamide Administration Rescues Cognitive Deficit and Reduces Neuroinflammation, Oxidative Stress, and Glutamate Levels in A Transgenic Murine Model of Alzheimer's Disease.

Authors:  Sarah Beggiato; Maria Cristina Tomasini; Tommaso Cassano; Luca Ferraro
Journal:  J Clin Med       Date:  2020-02-05       Impact factor: 4.241

6.  Analysis of behavioral management for dental treatment in patients with dementia using the Korean National Health Insurance data.

Authors:  Taeksu Kim; Seong In Chi; Hyuk Kim; Kwang-Suk Seo
Journal:  J Dent Anesth Pain Med       Date:  2021-10-01

Review 7.  Recent Developments in Microfluidic Technologies for Central Nervous System Targeted Studies.

Authors:  Maria Inês Teixeira; Maria Helena Amaral; Paulo C Costa; Carla M Lopes; Dimitrios A Lamprou
Journal:  Pharmaceutics       Date:  2020-06-11       Impact factor: 6.321

Review 8.  Molecular mechanisms in Alzheimer's disease and the impact of physical exercise with advancements in therapeutic approaches.

Authors:  Kiran Kumar Siddappaji; Shubha Gopal
Journal:  AIMS Neurosci       Date:  2021-03-19

Review 9.  The Beneficial Role of Natural Endocrine Disruptors: Phytoestrogens in Alzheimer's Disease.

Authors:  Anita Domańska; Arkadiusz Orzechowski; Anna Litwiniuk; Małgorzata Kalisz; Wojciech Bik; Agnieszka Baranowska-Bik
Journal:  Oxid Med Cell Longev       Date:  2021-09-03       Impact factor: 6.543

10.  β-Amyloid Clustering around ASC Fibrils Boosts Its Toxicity in Microglia.

Authors:  Lea L Friker; Hannah Scheiblich; Inga V Hochheiser; Rebecca Brinkschulte; Dietmar Riedel; Eicke Latz; Matthias Geyer; Michael T Heneka
Journal:  Cell Rep       Date:  2020-03-17       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.